Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

A comparative view on vitamin C effects on αβ‐ versus γδ T‐cell activation and differentiation

(2020) Christian Peters et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

(2019) Mohammed Alnaggar et al.   Journal for ImmunoTherapy of Cancer

A Structural Change in Butyrophilin upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation

(2019) Yunyun Yang et al.   IMMUNITY

Vitamin C promotes the proliferation and effector functions of human γδ T cells

(2019) Léonce Kouakanou et al.   Cellular & Molecular Immunology

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

(2019) Zsolt Sebestyen et al.   NATURE REVIEWS DRUG DISCOVERY

Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor–modified effector cells

(2018) Lin Xiao et al.   CYTOTHERAPY

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Butyrophilin3A proteins and Vγ9Vδ2 T cell activation

(2018) Siyi Gu et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer

(2018) Timm Hoeres et al.   Frontiers in Immunology

Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy

(2018) Jonathan Fisher et al.   Frontiers in Immunology

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects

(2018) Yuan Hu et al.   Engineering

γδ T cells provide the early source of IFN-γ to aggravate lesions in spinal cord injury

(2017) Guodong Sun et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Adoptive Transfer of Phosphoantigen-Specific γδ T Cell Subset AttenuatesMycobacterium tuberculosisInfection in Nonhuman Primates

(2017) Arwa Qaqish et al.   JOURNAL OF IMMUNOLOGY

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy

(2017) Dominique Bollino et al.   Translational Research

Current Advances in γδ T Cell-Based Tumor Immunotherapy

(2017) Elena Lo Presti et al.   Frontiers in Immunology

Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays

(2017) Marie Tosolini et al.   OncoImmunology

Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape

(2016) Malte Mohme et al.   Nature Reviews Clinical Oncology

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

(2016) Rizwan Romee et al.   Science Translational Medicine

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Targeted Activation of Human Vγ9Vδ2-T Cells Controls Epstein-Barr Virus-Induced B Cell Lymphoproliferative Disease

(2014) Zheng Xiang et al.   CANCER CELL

γδ T Cells and Their Potential for Immunotherapy

(2014) Yan-Ling Wu et al.   International Journal of Biological Sciences

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Natural killer cell lines in tumor immunotherapy

(2012) Min Cheng et al.   Frontiers of Medicine

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

(2011) Hirohito Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice

(2011) Wenwei Tu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆

(2010) Jun Nakajima et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Bromohydrin Pyrophosphate-stimulated Vγ9δ2 T Cells Expanded Ex Vivo From Patients With Poor-Prognosis Neuroblastoma Lyse Autologous Primary Tumor Cells

(2010) Jamel Chargui et al.   JOURNAL OF IMMUNOTHERAPY

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

(2008) Anke J. Roelofs et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*

(2008) M. Kondo et al.   CYTOTHERAPY